![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1761169
¼¼°èÀÇ Ã¼¿Ü Æó ¸ðµ¨ ½ÃÀå : ½ÃÀå ±Ô¸ð, ¿¹Ãø, Á¡À¯À², µ¿Çâ, ¼ºÀå±âȸ ºÐ¼® º¸°í¼ - À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°(2021-2031³â)In Vitro Lung Models Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Application, End User, and Geography |
ü¿Ü Æó ¸ðµ¨ ½ÃÀå ±Ô¸ð´Â 2024³â 4¾ï 4,635¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2031³â¿¡´Â 15¾ï 3,011¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ½ÃÀåÀº 2025-2031³â CAGR 19.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â È£Èí±â Áúȯ ±ÞÁõ, µ¿¹° ½ÇÇèÀ» ´ëüÇÒ Ã¼¿Ü Æó ¸ðµ¨ÀÇ Ã¤Åà Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. °Ô´Ù°¡ Á¾¾çÇп¡¼ÀÇ 3D ¹è¾ç ¹× AI ÀÀ¿ëÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» ²ø¾î¿Ã¸± °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ±×·¯³ª ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·Àº ½ÃÀåÀÇ ¾ïÁ¦ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.
Global Initiative on Chronic Obstructive Lung Disease(¸¸¼º Æó»ö¼º ÆóÁúȯ¿¡ °üÇÑ ¼¼°è ÀÌ´Ï¼ÅÆ¼ºê)°¡ ¹ßÇ¥ÇÑ º¸°í¼¿¡ µû¸£¸é, Æó»ö¼º ÆóÁúȯ(COPD)À» ¾Î°í ÀÖ´Â »ç¶÷Àº 6,500¸¸ ¸í¿¡ À̸£¸ç, ¸Å³â 300¸¸ ¸í °¡±îÀÌ ÀÌ ÁúȯÀ¸·Î »ç¸ÁÇϰí ÀÖ¾î ¼¼°è Á¦4À§ÀÇ »ç¸Á ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. 2023³â ¹Ì±¹ÆóÇùȸ µ¥ÀÌÅÍ¿¡ µû¸£¸é, ¾à 3,400¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ Ãµ½ÄÀ̳ª COPD µî ¸¸¼º ÆóÁúȯÀ» ¾Î°í ÀÖ½À´Ï´Ù. 2022³â¿¡´Â ¹Ì±¹ Àα¸ÀÇ 4.6%ÀÎ 1,170¸¸ ¸íÀÇ ¼ºÀÎÀÌ COPD Áø´ÜÀ» ¹Þ¾Ò½À´Ï´Ù. 2020³â¿¡ European Respiratory Journal¿¡ °ÔÀçµÈ ³í¹®¿¡ ÀÇÇϸé, 3,658¸¸ ¸íÀÇ À¯·´ÀÎÀÌ COPD¿¡ ÀÌȯÇß´Ù°í º¸°íµÇ¾úÀ¸¸ç, 2050³â¿¡´Â 4,945¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ¾î »ó´ëÀûÀ¸·Î 35.2% Áõ°¡ÇÏ°Ô µË´Ï´Ù. °³¹ßµµ»ó±¹¿¡¼ÀÇ Èí¿¬ º¸±Þ°ú °í¼Òµæ ±¹°¡¿¡¼ÀÇ °í·ÉÈ¿¡ µû¶ó COPD À¯º´·üÀº ÇâÈÄ 40³â°£ »ó½ÂÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ Ãß°è¿¡ µû¸£¸é COPD´Â 2030³â±îÁö ¼¼°èÀÇ ÁÖ¿ä »çÀÎ Áß Çϳª°¡ µÉ Àü¸ÁÀ̸ç, 2060³â±îÁö COPD ¹× °ü·Ã Áúȯ¿¡ ÀÇÇÑ »ç¸ÁÀÚ´Â ¿¬°£ 540¸¸ ¸íÀ» ³Ñ´Â °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù.
µû¶ó¼ È£Èí±â ÁúȯÀº Áúº´ÀÇ ¸ÞÄ¿´ÏÁòÀ» ÀÌÇØÇϰí È¿°úÀûÀÎ Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇÑ °í±Þ ¿¬±¸ ¸ðµ¨ ¼ö¿ä¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.
Á¤¹Ð Àý´Ü Æó ½½¶óÀ̽º(PCLS)¿Í °°Àº ½ÃÇè°ü ³» Æó ¸ðµ¨Àº ±âµµ ¼öÃà°ú ¿°Áõ ¿¬±¸¸¦ °¡´ÉÇÏ°Ô Çϰí õ½Ä ¹× ±âŸ È£Èí±â Áúȯ¿¡ ´ëÇÑ »õ·Î¿î Ä¡·á Ç¥ÀûÀÇ Æò°¡¸¦ ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù. ·· ¿Â ĨÀº Àΰ£ ÆóÀÇ »ý¸®Àû »óŸ¦ ÀçÇöÇϱâ À§ÇØ °³¹ßµÇ¾ú½À´Ï´Ù. ¹Ì½Ã°£ ´ëÇÐÀÇ 'lung-on-a-chip' µð¹ÙÀ̽º´Â ¹Ì¼¼ÇÑ À¯·Î¸¦ °®´Â ÇÃ¶ó½ºÆ½ Ĩ »ó¿¡¼ ¹è¾çÇÑ Àΰ£ Æó Á¶Á÷ ¼¼Æ÷¸¦ ÀÌ¿ëÇØ Æó ¼ÓÀÇ »óŸ¦ ½Ã¹Ä·¹À̼ÇÇϰí Áúȯ¿¡ ´ëÇÑ »õ·Î¿î Áö°ßÀ» Á¦°øÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌó·³ È¿°úÀûÀÎ Ä¡·á¿Í ¿¬±¸¸ðµ¨¿¡ ´ëÇÑ ¼ö¿äÀÇ Áõ´ë°¡ ½ÃÇè°ü ³» Æó¸ðµ¨ ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.
°Ô´Ù°¡, 2Â÷¿ø(2D) ¼¼Æ÷ ¹è¾ç°ú ´ÜÃþ ¹è¾çÀº ºñ¿ë È¿À²ÀûÀ̰í, 󸮷®ÀÌ ³ô°í, º¹Á¦°¡ ¿ëÀÌÇϸç, °á°úÀÇ ÇØ¼®ÀÌ ¿ëÀÌÇϱ⠶§¹®¿¡ ¼¼Æ÷ »ý¹°Çп¡¼ ÁúȯÀÇ ¿¬±¸³ª ¾àÁ¦ ½ºÅ©¸®´×¿¡ ³Î¸® ÀÌ¿ëµÇ°í ÀÖ½À´Ï´Ù. ±×·¸Áö¸¸, »ì¾ÆÀִ ȯÀÚ Á¾¾çÀÇ 3Â÷¿ø Á¾¾ç ¹Ì¼Ò ȯ°æ(TME)¿¡ Á¸ÀçÇÏ´Â µ¿Àû »óÈ£ÀÛ¿ëÀÇ º¹ÀâÇÑ ³×Æ®¿öÅ©¸¦ ÀçÇöÇϱ⿡´Â ºÒÃæºÐÇÕ´Ï´Ù. ÀÌ Ãø¸éÀº ¾ÏÀÇ °Åµ¿À̳ª ¾à¹° ¹ÝÀÀÀ» ¸ðµ¨¸µÇϰųª ȯÀÚÀÇ »ý°Ë¿¡¼ ¾Ï¼¼Æ÷ÁÖ¸¦ ºÐ¸®ÇØ 2Â÷¿ø ¹è¾çÀ¸·Î À¯ÁöÇÏ´Â ´É·ÂÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ 2Â÷¿ø ¼¼Æ÷ ¹è¾çÀº ±âÃÊÀûÀÎ °ÍÀ̱â´Â ÇÏÁö¸¸ in vivo¿¡¼ÀÇ Æó¾ÏÀ» Ư¡Áþ´Â º¹ÀâÇÑ TME¿Í ¼¼Æ÷ »óÈ£ÀÛ¿ëÀ» ÀçÇöÇϱ⿡´Â ºÒÃæºÐÇÕ´Ï´Ù. ¾Ï ¿¬±¸°¡ Áøº¸ÇÔ¿¡ µû¶ó µ¿¹° ¸ðµ¨ ÀÛ¼º¿¡ ÀÌ¿ëµÇ´Â µ¿¹°ÀÇ ¼öµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ µ¿¹°µé¿¡´Â ¸¶¿ì½º, ·¹Æ®, ±âŸ À¯»çÁ¾ÀÌ Æ÷ÇԵ˴ϴÙ. ±×·¸Áö¸¸, µ¿¹° ¸ðµ¨Àº ÀüÀÓ»ó ½ÃÇè¿¡¼ ¾òÀº Áö°ßÀ» È¿°úÀûÀÎ ÀÓ»ó Ä¡·á¿¡ ¿¬°á½ÃŰ´Â ¼º°ø·üÀÌ ³·½À´Ï´Ù. ÀÌ·¯ÇÑ ÇѰ迡 ´ëóÇϱâ À§ÇØ ¿¬±¸´Â º¸´Ù »ý¸®ÇÐÀûÀ¸·Î ÀûÀýÇÑ Àΰ£ ü¿Ü ¸ðµ¨(3D ¼¼Æ÷ ¹è¾ç ¸ðµ¨)-½ºÆä·ÎÀ̵å, ¿À¸£°¡³ëÀ̵å, Á¾¾ç¼¼Æ÷, ¸¶ÀÌÅ©·Î À¯Ã¼ ½Ã½ºÅÛ µî-À¸·Î ÀÌÇàÇϰí ÀÖÀ¸¸ç, À̵éÀº ÀÓ»ó¿¡¼ °üÂûµÇ´Â TME, À¯ÀüÀÚ ¹ßÇö, ¾à¹° ÀÀ´äÀ» º¸´Ù Àß ¸ð¹æÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸ðµ¨Àº ƯÈ÷ Æó¾Ï ¿¬±¸¿¡¼ ¾àÁ¦ÀÇ À¯È¿¼ºÀ» °ËÁõÇϰí ÀüÀÓ»ó ½ÃÇèÀ» °³¼±Çϱâ À§ÇØ ÇʼöÀûÀÔ´Ï´Ù. ¾àÁ¦ ½ºÅ©¸®´×¿¡ ÀÖ¾î¼ 3D ¸ðµ¨ÀÇ ÅëÇÕÀº 2D ¹è¾çÀ¸·ÎºÎÅÍ ¾òÀº Áö°ßÀ» °ËÁõÇϰí Ç×¾ÏÁ¦ÀÇ È¿°ú¸¦ Æò°¡Çϱâ À§Çؼ ºÒ°¡°áÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù¹ýÀº ¾Ï Ä¡·áÁ¦ÀÇ ½ºÅ©¸®´×¿¡ À¯ÀÍÇÏ´Ù´Â °ÍÀÌ Áõ¸íµÇ°í ÀÖÀ¸¸ç, Æó¾Ï ¿¬±¸¿Í Ä¡·á °³¹ßÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â ¸Å¿ì Áß¿äÇÑ µµ±¸·Î ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. Æó¾Ï ¾à¸®ÇÐ ¿¬±¸¿¡¼ 3D ¼¼Æ÷ ¹è¾ç ¸ðµ¨ÀÇ »ç¿ëÀº ÆóÁúȯÀÇ ÀÌÇØ¿Í Ä¡·á¿¡ ´ëÇÑ Á¢±Ù ¹æ½ÄÀÇ ÆÐ·¯´ÙÀÓ º¯È¸¦ ÀǹÌÇÕ´Ï´Ù.
°æÀï¾÷üº° ºÐ¼®¿¡¼´Â Á¦Ç° Æ÷Æ®Æú¸®¿À(Á¦Ç° ¸¸Á·µµ, Á¦Ç° Ư¡, À̿밡´É¼º), ÃÖ±Ù ½ÃÀå µ¿Çâ(ÇÕº´ ¹× Àμö, ½ÅÁ¦Ç° Ãâ½Ã ¹× °È, ÅõÀÚ ¹× ÀÚ±Ý Á¶´Þ, ¼ö»ó, ÇÕÀÇ, Á¦ÈÞ ¹× Çù·Â, ÀÎÁö, È®´ë), °æÀï ±¸µµÀÇ º¸´Ù ÁÁÀº ÀÇ»ç°áÁ¤°ú ÀÌÇØ¸¦ µ½´Â Áö¸®Àû Á¸Àç°¨¿¡ ±Ù°ÅÇØ ½ÃÇè°ü³» Æó¸ðµ¨ ½ÃÀåÀ» Æò°¡ ¹× ºÐ·ùÇϰí ÀÖ½À´Ï´Ù. º» º¸°í¼¿¡¼´Â, ¼¼°èÀÇ ½ÃÇè°ü³» Æó¸ðµ¨ ½ÃÀå¿¡ ÀÖ¾î¼ÀÇ ÁÖ¿ä º¥´õÀÇ ÃÖ±ÙÀÇ Áß¿äÇÑ µ¿Çâ°ú Çõ½Å¿¡ ´ëÇØ ±íÀÌ Á¶»çÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ½ÃÀå ±â¾÷À¸·Î´Â MatTek Corp, Lonza Group AG, Emulate, Inc, CN Bio Innovations Ltd, PromoCell GmbH, Charles River Laboratories International Inc, MIMETAS BV, InSphero AG, Organovo Holdings Inc, Draper, Inc, Epithelix, AlveoliX AG, American Type Culture Collection(ATCC)ÀÔ´Ï´Ù.
À¯Çü¿¡ µû¶ó ½ÃÀåÀº 3D ¸ðµ¨°ú 2D ¸ðµ¨·Î ³ª´¹´Ï´Ù. 3D ¸ðµ¨Àº 2024³â ü¿Ü Æó ¸ðµ¨ ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, 2024-2031³â¿¡ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ü¿Ü Æó ¸ðµ¨ ½ÃÀåÀº ¿ëµµº°·Î, â¾à ¹× µ¶¼º ¿¬±¸, »ý¸®ÇÐÀû ¿¬±¸, Àç»ý ÀÇ·á, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2024³âÀÇ Ã¼¿Ü Æó ¸ðµ¨ ½ÃÀå¿¡¼´Â â¾à ¹× µ¶¼º ¿¬±¸ ºÐ¾ß°¡ ÃÖ´ëÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
ÃÖÁ¾ »ç¿ëÀÚº°·Î ü¿Ü Æó ¸ðµ¨ ½ÃÀåÀº Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, Çмú±â°ü ¹× ¿¬±¸±â°ü, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2024³â ü¿Ü Æó ¸ðµ¨ ½ÃÀå¿¡¼´Â Á¦¾à ¹× ¹ÙÀÌ¿À ±â¾÷ ºÎ¹®ÀÌ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
ü¿Ü Æó ¸ðµ¨ ½ÃÀå¿¡¼ »ç¾÷À» Àü°³ÇÏ´Â ±â¾÷Àº ´Ù¾çÇÑ À¯±âÀû ¹× ¹«±âÀû Àü·«À» ä¿ëÇϰí ÀÖ½À´Ï´Ù. À¯±âÀû Àü·«¿¡´Â ÁÖ·Î Á¦Ç° Ãâ½Ã ¹× Á¦Ç° ½ÂÀÎÀÌ Æ÷ÇԵ˴ϴÙ. ½ÃÀå¿¡¼ º¼ ¼ö ÀÖ´Â ¹«±âÀûÀÎ ¼ºÀå Àü·«Àº Àμö, Á¦ÈÞ, ÆÄÆ®³Ê½ÊÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀå Àü·«¿¡ ÀÇÇØ, ½ÃÀå Âü°¡ ±â¾÷Àº »ç¾÷À» È®´ëÇØ, Áö¸®Àû Á¸Àç°¨À» ³ôÀÌ´Â °Í°ú µ¿½Ã¿¡, ½ÃÀå ÀüüÀÇ ¼ºÀå¿¡ °øÇåÇÒ ¼ö ÀÖ½À´Ï´Ù. °Ô´Ù°¡ Àμö³ª Á¦ÈÞ µîÀÇ Àü·«Àº °í°´ ±â¹ÝÀ» °ÈÇϰí Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®´ëÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ½ÃÇè°ü ³» Æó¸ðµ¨ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷¿¡ ÀÇÇÑ Áß¿äÇÑ ¹ßÀüÀÇ ÀϺθ¦ ÀÌÇÏ¿¡ Á¦½ÃÇÕ´Ï´Ù.
2024³â 9¿ù, ½ÃÇè°ü³» Àΰ£ Á¶Á÷ÀÇ °³¹ßÀ» Àü¹®À¸·Î ÇÏ´Â ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ÀÎ MatTek Life Sciences»ç´Â Áß±¹À» °ÅÁ¡À¸·Î ÇÏ´Â »ý¸í°úÇÐ ¿¬±¸¼ÒÀÎ CellEx»ç¿¡ µ¿»çÀÇ ±â°üÇü Àΰ£ Á¶Á÷À» ¶óÀ̼±½ÌÇÏ´Â °ÍÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Àü·«Àû Á¦ÈÞ´Â ¿¬±¸ °³¹ß, ÀǾàǰ °³¹ß, ¾ÈÀü¼º Æò°¡ ¿ëµµ¿¡ ÀÖ¾î¼ Àΰ£ Á¶Á÷ÀÇ Áøº¸ ¹× À̿뿡 ȹ±âÀûÀÎ »ç°ÇÀÔ´Ï´Ù.
2023³â 6¿ù Â÷¼¼´ë ü¿Ü ¸ðµ¨ Á¦°ø¾÷üÀÎ ¿¡¹Ä·¹ÀÌÆ®»ç´Â Á¶±â ¾×¼¼½º ÇÁ·Î±×·¥À» ÅëÇØ Emulate Chip-A1 Accessible ChipÀÇ ¹ß¸Å¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ »õ·Î¿î Organ-ChipÀÇ µðÀÚÀÎÀº ½ºÆ®·¹Ä¡³ª Ç÷οì¶ó°í ÇÏ´Â »ýü¿ªÇÐÀû ÈûÀ» ÀÌ¿ëÇØ Á¶Á÷°ú Ç÷°üÀÇ ÀÎÅÍÆäÀ̽º¸¦ ¸ðµ¨ÈÇÑ ¿À¸®Áö³ÎÀÇ Chip-S1À» È®ÀåÇÑ °ÍÀ¸·Î, À¯Àú´Â »óÇÇ ¹è¾ç è¹ö³»¿¡¼ º¸´Ù µÎ²¨¿î Á¶Á÷À» Á¦ÀÛÇØ, ±¹¼Ò Åõ¿©³ª ¿¡¾î·ÎÁ¹È µîÀÇ ¾à¹° Ä¡·áÀÇ ¿É¼ÇÀ» Ãß°¡ÇÒ ¼ö°¡ ÀÖ½À´Ï´Ù.
The In Vitro lung models market size is projected to reach US$ 1,530.11 million by 2031 from US$ 446.35 million in 2024. The market is estimated to register a CAGR of 19.4% during 2025-2031. Major factors driving the market growth include a surging prevalence of respiratory diseases and the rising adoption of in vitro models as an alternative to animal testing. Further, Applications of 3D cultures and AI in oncology is likely to boost the market during the forecast period. However, lack of skilled professionals are among the market deterrents.
According to a report published by the Global Initiative on Chronic Obstructive Lung Disease, ~65 million people suffer from obstructive pulmonary disease (COPD), and nearly 3 million people die from the disease each year, making it the fourth leading cause of mortality worldwide. According to the 2023 American Lung Association data, ~34 million Americans were affected by chronic lung diseases such as asthma and COPD. In 2022, ~11.7 million adults, or 4.6% of the population in the US, were diagnosed with COPD. As per an article published in the European Respiratory Journal in 2020, 36.58 million Europeans were reported to have COPD, which is projected to reach 49.45 million by 2050, representing a 35.2% relative increase. With the growing prevalence of smoking in developing countries and the aging population in high-income countries, the COPD prevalence is projected to rise over the next forty years. As per the World Health Organization (WHO) estimates, COPD will become one of the leading causes of death worldwide by 2030, and it is estimated that by 2060, there will be more than 5.4 million deaths yearly due to COPD and related conditions.
Therefore, respiratory diseases is spurring the demand for advanced research models to understand disease mechanisms and develop effective treatments.
In vitro lung models, such as precision-cut lung slices (PCLS), allow the study of airway constriction and inflammation, facilitating the evaluation of novel therapeutic targets for asthma and other respiratory conditions. Lung-on-a-chip devices have been developed to replicate the physiological conditions of the human lung. The University of Michigan's "lung-on-a-chip" device uses human lung-tissue cells cultured on a plastic chip with microscopic channels to simulate the conditions inside the lungs, providing new insights into diseases. Thus, the increasing demand for effective treatments and research models fuels the growth of the in vitro lung model market.
Moreover, two-dimensional (2D) cell cultures, or monolayers, are widely used in cellular biology to study diseases and for drug screening due to their cost-effectiveness, high throughput, easy replication, and results interpretation. However, they fall short in replicating the complex network of dynamic interactions present in the three-dimensional tumor microenvironment (TME) of living patient tumors. This aspect limits their ability to model cancer behavior and drug responses, as well as to isolate and maintain cancer cell lines from patient biopsies in 2D cultures. Traditional 2D cell cultures, while foundational, fall short in replicating the intricate TME and cellular interactions that characterize lung cancers in vivo. As cancer research advances, an increasing number of animals are being utilized in the creation of animal models. These animals include mice, rats, and other similar species. However, animal models exhibit low success rates in translating preclinical findings into effective clinical treatments; this has raised concerns about their reliability as predictors of human responses. To address these limitations, research is shifting toward more physiologically relevant human in vitro models (3D cell culture models)-such as spheroids, organoids, tumoroids, and microfluidic systems-that better mimic the TME, gene expression, and drug responses observed clinically. These models are critical for validating drug efficacy and improving preclinical testing, especially in lung cancer research. Integrating 3D models in drug screening is essential to validate findings from 2D cultures and assess the effects of anticancer drugs. Such approaches have proven to be fruitful for cancer drug screening and are emerging as a pivotal tool in shaping the future of lung cancer research and therapeutic development. The use of 3D cell culture models in lung cancer pharmacology research represents a paradigm shift in the approach toward understanding and treating lung diseases.
The comparative company analysis evaluates and categorizes the in vitro lung models market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global in vitro lung models market. The key market players are MatTek Corp, Lonza Group AG, Emulate, Inc, CN Bio Innovations Ltd, PromoCell GmbH, Charles River Laboratories International Inc, MIMETAS BV, InSphero AG, Organovo Holdings Inc, Draper, Inc, Epithelix, AlveoliX AG, and American Type Culture Collection (ATCC).
Based on type, the market is divided into 3D Models and 2D Models. The 3D Models segment held the largest In Vitro Lung Model Market share in 2024, and it is expected to register the highest CAGR during 2024-2031.
By application, In Vitro Lung Model market is segmented into drug discovery and toxicology studies, physiological research, regenerative medicine, and others. The drug discovery and toxicology studies segment held the largest share of the in vitro lung model market in 2024.
Per end user, In Vitro Lung Model market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and others. The pharmaceutical and biotechnology companies segment held the largest share of the In Vitro lung model market in 2024.
Various organic and inorganic strategies are adopted by companies operating in the in vitro lung models market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, along with contributing to the overall market growth. Furthermore, strategies such as acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the in vitro lung models market are listed below.
In September 2024, MatTek Life Sciences, a biotech company specializing in the development of in vitro human tissues, announced the licensing of its organotypic human tissues to CellEx, a life science laboratory based in China. This strategic collaboration marks a milestone in the advancement and utilization of human tissues for research, pharmaceutical development, and safety assessment applications.
In June 2023, Emulate, Inc., a provider of next-generation in vitro models, announced the launch of the Emulate Chip-A1 Accessible Chip through an early access program. This new Organ-Chip design expands on the original Chip-S1-which models tissue-vascular interfaces with relevant biomechanical forces such as stretch and flow-by allowing users to create thicker tissues within the epithelial culture chamber and apply additional drug treatment options, including topical or aerosolized applications.